Latest News

A new low-carbon albuterol inhaler shows therapeutic equivalence to original options, suggesting reduced emissions and improved sustainability for patients with asthma and other respiratory conditions.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

Total cholesterol and triglyceride levels were linked to an increased risk of Alzheimer-related declines in cognitive function, while high-density lipoprotein cholesterol provided a protective effect.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

Lawmakers weigh cost concerns, clinical outcomes, and regulatory barriers as access to these medications evolves.

Explore the impact of extrapyramidal symptoms on patients, including drug-induced parkinsonism and dystonia, and the importance of early detection and management.

A phase 2 trial suggests a stepwise regimen using liposomal irinotecan followed by oxaliplatin may improve progression-free survival over standard treatment.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

Pharmacy professionals should make informed decisions regarding their individual career paths.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Language preference significantly impacts access to continuous glucose monitors for type 2 diabetes, revealing critical disparities in diabetes care.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related hot flashes, offers women a new, effective relief option.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

This quiz was created in collaboration with PTCE™.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Influenza vaccination provided direct, non–infection-based benefits in older adults.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.